Discovery of 4,6-Disubstituted Pyrimidine Derivatives as Novel Dual VEGFR2/FGFR1 Inhibitors. 2021

Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, P. R. China.

Abnormalities in the FGFRs signaling pathway and VEGFR2 amplification often occur in a variety of tumors, and they synergistically promote tumor angiogenesis. Studies have shown that the up-regulation of FGF-2 is closely related to the resistance of VEGFR2 inhibitors. Activation of the FGFRs signal is a signal of compensatory angiogenesis after VEGFR2 resistance. Dual VEGFR2/FGFR1 inhibitors contribute to overcoming the resistance of VEGFR2 inhibitors and inhibit tumor growth significantly. Based on this, we designed and synthesized a series of 4,6-disubstituted pyrimidine derivatives as dual VEGFR2/FGFR1 inhibitors by the molecular hybridization strategy. 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-{6-[(4-methoxyphenyl)amino]pyrimidin-4-yl}-1-methylurea (8b) had the best inhibitory activities against VEGFR2 and FGFR1 at 10 μM (82.2 % and 101.0 %, respectively), it showed moderate antiproliferative activities against A549 and KG-1 cell lines as well. Besides, molecular docking was also carried out to study the binding mode of 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-{6-[(4-methoxyphenyl)-amino]-pyrimidin-4-yl}-1-methylurea (8b) with VEGFR2 and FGFR1. These studies reveal that this series of compounds deserve further optimization.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D051496 Receptor, Fibroblast Growth Factor, Type 1 A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 contains three extracellular IMMUNOGLOBULIN C2-SET DOMAINS and is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM. Fibroblast Growth Factor Receptor 1,CD331 Antigen,FGFR1 Protein,FGFR1 Tyrosine Kinase,Fibroblast Growth Factor Soluble Receptor 1,fms-Like Tyrosine Kinase-2,Antigen, CD331,fms Like Tyrosine Kinase 2

Related Publications

Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
February 2020, European journal of medicinal chemistry,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
May 2013, European journal of medicinal chemistry,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
September 2016, Bioorganic & medicinal chemistry letters,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
May 2018, Bioorganic & medicinal chemistry,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
September 2020, Molecules (Basel, Switzerland),
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
May 2010, Archives of pharmacal research,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
April 2017, ACS medicinal chemistry letters,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
February 2014, Bioorganic & medicinal chemistry,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
July 2020, Journal of medicinal chemistry,
Jin-Yang Zhang, and Wen-Jun Xue, and Min Wang, and Wen Li, and Ru Dong, and Ming-Tao Li, and Li-Ping Sun
December 2015, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!